# Eli Casdin

> Eli Casdin is a Series B investor at Casdin Capital backing Biotechnology and Health Care. See 28 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Casdin Capital](https://shizune.co/investors/profile/casdin-capital)
- Location: New York, United States
- Total investments: 28
- Last investment: Apr 2024
- Lead investor: 64%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/eli-casdin-2753777/

Eli Casdin is a Series B investor at Casdin Capital in New York focused on Biotechnology and Health Care. Eli Casdin

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 15 | 54% |
| Health Care | 10 | 36% |
| Therapeutics | 8 | 29% |
| Medical | 5 | 18% |
| Life Science | 4 | 14% |

23 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 6 | 21% |
| Series A | 5 | 18% |
| Series C | 5 | 18% |
| Post-IPO Equity | 4 | 14% |
| Series E | 2 | 7% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 16 | 57% |
| France | 1 | 4% |
| The Netherlands | 1 | 4% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Century Therapeutics | Century Therapeutics is a developer of allogeneic living drugs created to offer treatment for cancer. The company's genetically-engineered, iPSC-derived immune effector cell products are designed to specifically target hematologic and solid cancers by harnessing the power of adult stem cells, providing patients with an unparalleled opportunityto advance the course of cancer care. | $60M | Post-IPO Equity | Apr 11, 2024 |  |
| iVexSol | iVexSol is a newly formed viral vector manufacturing company | $23.8M | Series A | Jan 26, 2023 |  |
| Leyden Labs | Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains ofrespiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. | $140M | Series B | Jan 25, 2022 |  |
| Standard BioTools | Fluidigm Corporation develops and distributes systems based on the properties of integrated fluidic circuits to control precisely fluids on a nano volume scale. The company's product line includes the TOPAZ system, which is used for protein crystallization; and the BioMark system, which is used for genetic analysis. Fluidigm Corporation wasfounded as Mycometrix Corporation in 1999 and was renamed as Fluidigm Corporation in 2001. The company is based in San Francisco, California. | $250M | Post-IPO Equity | Jan 24, 2022 |  |
| DNA Script | DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results. | $35M | Series C | Jan 04, 2022 |  |
| EQRx | EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines.By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the companyseeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.The company was founded in 2019 and is based in Cambridge, Massachusetts, United States. | $1.2B | Post-IPO Equity | Dec 17, 2021 |  |
| DNA Script | DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results. | $165M | Series C | Oct 26, 2021 |  |
| Tango Therapeutics | Tango Therapeutics operator of a biotechnology company created to discover novel drug targets and deliver the next generation of targeted therapies to people with cancer. The company's research leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer that are focused onthree core areas, including counteracting tumor suppressor gene loss, reversing the ability of cancer cells to evade the immune system and identifying novel combinations, enabling patients to get therapies that are more effective than single-agent therapy. | $186M | Post-IPO Equity | Aug 11, 2021 |  |
| LetsGetChecked | LetsGetChecked is an at-home health testing platform that connects customers to regulated laboratory testing to better manage and control one's individual health. LetsGetChecked is making healthcare and diagnostics open and patient-led, empowering people to use technology in a simple yet powerful way. This offers consumers greater control overtheir individual health. LetsGetChecked is headquartered in New York, New York, with tests covering general wellness, sexual health, women's health, and men's health, and is available nationwide, as well as in Canada and Europe. | $150M | Series D | Jun 08, 2021 |  |
| C2i Genomics | C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations.The cancer intelligence company is developing a platform that can perform whole-genome sequencing using only 2 milliliters of blood. Its ultra-sensitive liquid biopsy assay allows physicians to monitor patient treatment response and detecttreatment failure or disease recurrence months and potentially years earlier than current monitoring methods. C2i’s cancer diagnostics service uses artificial intelligence pattern recognition and the whole-genome analysis to spot trace amounts of cancer much quicker, in about a week, to inform better treatment decisions and ultimately save lives. The company aims to help patients avoid unnecessary overtreatment with toxic chemotherapy or radiation, as well as to prevent them from going without treatment while cancer quietly grows and metastasizes.In 2019, Boris Oklander, Asaf Zviran, and Ezra Sofer established the company in New York, New York. | $100M | Series B | Apr 15, 2021 |  |

10 of 28 investments shown.

## Co-investors
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 10 deals together
- [Fidelity](https://shizune.co/investors/profile/fidelity-investments) — VC Fund, 6 deals together
- [Boxer Capital](https://shizune.co/investors/profile/boxer-capital) — VC Fund, 5 deals together
- [Fidelity](https://shizune.co/investors/profile/fidelity-management-and-research-company) — VC Fund, 5 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 4 deals together
- [ArrowMark Partners](https://shizune.co/investors/profile/arrowpoint-partners) — VC Fund, 3 deals together

## About Casdin Capital

VC Fund · New York, United States

Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets undermanagement.

4 contacts available at Casdin Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Suzanne Angell | Director of Research | https://shizune.co/investors/profile/suzanne-angell-fb8b |
| Eli Casdin | managing partner | https://shizune.co/investors/profile/eli-casdin |
| John Graziano | Platform Investor Relations & Syndication Lead | https://shizune.co/investors/profile/john-graziano-6430 |
| Lawrence Canzoneri | CFO | https://shizune.co/investors/profile/lawrence-canzoneri |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Eli Casdin invest in?

Eli Casdin invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 28 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Eli Casdin last invest?

The most recent investment recorded for Eli Casdin closed in Apr 2024. Shizune tracks 28 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co